Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial

OBJECTIVES: We sought to confirm in very early rheumatoid arthritis (ERA) a much greater superiority (30%) of first-line etanercept+methotrexate (ETN+MTX) over treat-to-target MTX (MTX-TT) than previously reported in ERA (14%); and explore whether ETN following initial MTX secures a comparable respo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Rheum Dis
Autors principals: Emery, Paul, Horton, Sarah, Dumitru, Raluca Bianca, Naraghi, Kamran, van der Heijde, Désirée, Wakefield, Richard J, Hensor, Elizabeth M A, Buch, Maya H
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Rheumatoid Arthritis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7147179/
https://ncbi.nlm.nih.gov/pubmed/31996367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2019-216539
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars